Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

1,246

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

July 14, 2023

Conditions

COVID-19 Pneumonia

Interventions

DRUG

GST-HG171/Ritonavir

dose of 150 mg GST-HG171 with 100 mg ritonavir

DRUG

Placebo

Trial Locations (1)

The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou

All Listed Sponsors

lead

Fujian Akeylink Biotechnology Co., Ltd.

INDUSTRY